Research Articles
The Cellular Recycling Center: How Protein Degradation Governs Health and Disease
Explore the ubiquitin-proteasome system, its role in protein degradation, connections to human diseases, and revolutionary therapeutic approaches like PROTAC technology.
Rewriting the Brain's Rules: How Targeted Protein Degradation Fights Neurodegenerative Diseases
Explore how Targeted Protein Degradation (TPD) is revolutionizing the treatment of neurodegenerative diseases by eliminating toxic proteins rather than just inhibiting them.
Taming the Guardian's Jailer: A New Weapon in the Fight Against Cancer
Explore the revolutionary approach of targeted MDM2 degradation using PROTACs as a novel cancer therapy that destroys cancer-causing proteins rather than just inhibiting them.
UBX-306: The Molecular Demolition Crew Revolutionizing Cancer Immunotherapy
Discover how UBX-306, a novel HPK1 degrader using PROTAC technology, is revolutionizing cancer immunotherapy by eliminating immune system brakes at the molecular level.
A Molecular Trojan Horse: New Hope in the Fight Against Leukemia
Discover how PROTAC molecular technology is revolutionizing leukemia treatment by degrading cancer-causing proteins with unprecedented efficacy.
The Cellular Double Agent: How Flipping a Cancer "Shield" into a "Kill Signal" Offers New Hope
Discover how scientists are turning the SUMO1 cancer protein shield into a kill signal using PROTAC degraders, offering new hope for cancer treatment.
Demolishing a Cancer Fortress: A New Two-Pronged Attack on Aggressive Lymphoma
Discover how PROTAC technology combined with combination therapies is revolutionizing treatment for Diffuse Large B-cell Lymphoma through targeted protein degradation.
Ubiquitinomics: Decoding the Cell's Master Switch
Explore the science of ubiquitinomics - how this tiny protein controls cellular functions and revolutionizes medicine through targeted protein degradation.
The VHL Hijack: How a Broken Cellular Cleanup Crew Fuels Kidney Cancer—and How Science Is Fighting Back
Exploring how VHL protein dysfunction drives kidney cancer and the innovative therapies targeting this pathway.
The DOT1L Destroyer: How a Molecular Pac-Man Could Revolutionize Leukemia Treatment
Discover how the first-in-class DOT1L PROTAC degrader MS2133 could revolutionize treatment for MLL-rearranged leukemia by completely eliminating the cancer-causing protein.